2012 Webcasts

Below are the links to webcasts for the keynote lectures, plenary and oral sessions,
case study discussions and the pre-congress workshop from the Congress.

The following specifications are not recommended to avoid play back issues.

PC – Click the link (PC)
Internet Explorer 7 or above
Screen resolution of 1024 x 768 or higher
Internet bandwidth of 750 kbps or higher

Mac – Click the link (MAC)
Mac OS x 10.4.8 or later
Safari 2.0.4 or later
Screen resolution of 1024 x 768 or higher
Internet bandwidth of 750 kbps or higher

HIV Drug-Drug Interactions Pre-Congress Workshop PCMAC
Saye Khoo, Liverpool, UK; Catia Marzolini, Basel, Switzerland; Jonathan Schapiro, Tel Aviv, Israel; Mauro Schechter, Rio de Janeiro, Brazil 

Welcome and introduction
David Back, Liverpool, UK
Mini talk: the problems of QTc prolongation
Krishna Prasad, London, UK
Case 1: hepatitis C and ARVs
Jürgen Rockstroh, Bonn, Germany
Case 2: cancer chemotherapy and ARVs
Ed Wilkins, Manchester, UK
Case 3: non oral meds and ARVs
Laura Waters, London, UK
Dilemma: what is the optimal timing for taking ARVs when you cross time zones
Alain Volny-Anne, Paris, France, and Saye Khoo
Closing Remarks

 Official Opening PCMAC
Bailie Philip Braat, Glasgow City Council Representative, Glasgow, UK
Graham Hart, University College London, London, UK

Keynote Lectures
Prevention of HIV-1 infection 2013: glimmers of hope PC – MAC
Myron S Cohen, Chapel Hill, USA
HIV eradication: virological chances and clinical perspectives PCMAC
Carlo-Federico Perno, Rome, Italy
From HIV to global health: opportunities and challenges  PCMAC
Wafaa El-Sadr, New York, USA

Monday 12 November  

ART for Prevention and Treatment
Pre-exposure prophylaxis: where are we in Europe? PCMAC
Jean-Michel Molina, Paris, France
Treatment in antiretroviral-naïve patients
When to start: as soon as possible PCMAC
Mike Saag, Birmingham, USA
When to start: not so fast PC MAC
Jens Lundgren, Copenhagen, Denmark
Late presenters: what can we do? PCMAC
Cristina Mussini, Modena, Italy
Panel discussion PC MAC

Clinical Challenges
HIV, co-morbidity and ageing PCMAC
Peter Reiss, Amsterdam, The Netherlands
TB and HIV: how can we reduce mortality? PCMAC
Stephen D Lawn, London, UK
HIV in women PCMAC
Fiona Mulcahy, Dublin, Ireland
Panel discussion  PCMAC

Poster Discussion Sessions: Complications and Toxicity PCMAC
Tenofovir induced acute kidney injury in HIV infected patients in western India: a resource limited setting perspective
Ameet Dravid, Pune, India
Late gadolinium enhancement and subclinical cardiac dysfunction on cardiac MRI in asymptomatic HIV positive Men
Aisling Loy, Dublin, Ireland
Impact of antiretroviral therapy (ART), immunosuppression and viraemia on lipid levels: the D:A:D Study
David A Kamara, London, UK
Nevirapine vs efavirenz in virologically suppressed patients: differences in lipoprotein subclasses and inflammatory biomarkers
Vicente Estrada, Madrid, Spain
Effects of switching to PI monotherapy on measures of lipoatrophy: meta-analysis of six radmoized HIV clinical trials
José R Arribas, Madrid, Spain

Poster Discussion Sessions: Clinical Pharmacology PCMAC
Impact of antiretroviral dosing frequency and daily pill burden on virological success rates in patients of the ICoNA cohort starting their first ART
Adriana Ammassari, Roma, Italy
Simultaneous population pharmacokinetic modelling of darunavir and ritonavir once daily in HIV-infected patients: evaluation of lower ritonavir dose
Laura Dickinson, Liverpool, UK
Pharmacokinetic profile of maraviroc 150 mg dosed with darunavir/ritonavir once daily,  with and without nucleoside analogues, in HIV-infected subjects
Borja Mora-Peris, London, UK
Effect of food on the pharmacokinetics of emtricitabine/rilpivirine/tenofovir disproxil fumarate single-tablet regimen
Susan Chuck, Foster City, USA
CYP2B6 G516T and ABCB-1 C3435T polymorphisms:implications for efavirenz associated liver toxicity in HIV/tuberculosis co-infected Thai adults
Sumonmal Uttayamakul, Muang District, Thailand
Therapeutic drug monitoring (TDM) of atazanavir in pregnancy
John Lambert, Dublin, Ireland 

Living Longer with ART
Review of life expectancy in people with HIV in settings with optimal ART access: what we know and what we don’t PCMAC
Caroline Sabin, London, London, UK
Currently available medications may not be sufficient for lifelong treatment of HIV PCMAC
James Jansson, Sydney, Australia
Life expectancy of HIV-1 positive individuals approaches normal conditional on response to antiretroviral therapy: UK Collaborative HIV Cohort study PCMAC
Margaret May, Bristol, UK
Panel Discussion PCMAC

The HIV Research Trust
Report on progress PCMAC
Robert Souhami, Chairperson of the HIV Research Trust
Clinical pharmacokinetics of antiretroviral drugs in Ugandan patients PCMAC
Mohammed Lamorde, Kampala, Uganda (Glasgow Resource Limited Scholar 2008; HIV Research Trust Scholar)

Current Guidelines in Antiretroviral Therapy: When and What to Start PCMAC
Case-based discussion held in collaboration with the International Antiviral Society-USA (IAS-USA)

Manuel Battegay, University Hospital Basel, Basel, Switzerland
Roy Gulick, Weill Medical College of Cornell University, New York, USA
Guidelines panel
International Antiviral Society-USA (IAS-USA)
Melanie Thompson, Atlanta, USA
European AIDS Clinical Society (EACS)
Nathan Clumeck, Brussels, Belgium
Department of Health and Human Services (DHHS)
Clifford Lane, Bethesda, USA
British HIV Association (BHIVA)
Ian Williams, London, UK
World Health Organization (WHO)
Stefano Vella, Rome, Italy

     Tuesday 13 November

Royal College of Physicians and Surgeons of Glasgow Lock LectureIntroducing the Lock Lecture PCMAC
Ian Anderson, Glasgow, UK
Treatment optimisation in low- and middle- income countries PCMAC
David Cooper, Sydney, Australia
Presentation by Royal College of Physicians and Surgeons of Glasgow PCMAC
Ian Anderson, Glasgow, UK

ART Dilemmas in Resouce-Limited Settings
Session held in collaboration with the International AIDS Society (IAS)
HAART roll-out in the new fiscal and economic environment PCMAC
Jean Paul Moatti, Marseille, France
Eliminating paediatric infections and keeping mothers alive PCMAC
Glenda Gray, Johannesburg, South Africa
ARV delivery in resource-poor settings and the risk of wide-scale resistance PCMAC
Silvia Bertagnolio, Geneva, Switzerland
Does early initiation of ART in infants affect virologic and resistance outcomes? Data from the CHER trial after 6 years of follow up PCMAC
Avy Violari, Johannesburg, South Africa
Evolution of resistance in pediatric patients with failure on antiretroviral therapy PCMAC
Catherine Orrell, Cape Town, South Africa
Panel discussion PCMAC

A Community Perspective on How To Treat Europe PCMAC
Session held in collaboration with the European AIDS Treatment Group (EATG)
Welcome, introduction and objectives
Brian West and Memory Sachikonye
Successes in treatment in Europe: country focus – Ukraine
Angela Skopenko, etwork of PLWH, Ukraine
Budget issues driving/affecting treatment choice
Simon Collins, UK Community Advisory Board (UK-CAB)/i-Base/European AIDS Treatment Group (EATG)
Treatment decisions brought about by budgetary restraints in countries such as Spain and Portugal
Luís Mendão, Grupo Português de Activistas sobre Tratamentos de VIH/SIDA (GAT)/European AIDS Treatment Group (EATG)
Future treatment choices/availability with generics in Europe
Jürgen Rockstroh, Bonn, Germany
Panel discussion
Summary and close

Drug Resistance 
Importance of minor variants and their detection (ultra-deep sequencing) in the management of HIV infection PCMAC
Roger Paredes, Barcelona, Spain
Antiviral activity of dolutegravir in subjects with failure on an integrase inhibitor-based regimen: week 24 phase 3 results from VIKING-3 PCMAC
Garrett Nichols, Research Triangle Park, USA
Selection in culture of HIV resistance to dolutegravir by mutations at integrase positions R263K and H51Y that diminish viral replication fitness PCMAC
Mark Wainberg, Montreal, Canada
Computational models that predict response to HIV therapy can reduce virological failure and therapy costs in resource-limited settings PCMAC
Andrew Revell, London, UK
Panel discussion  PC MAC

HIV HCV Co-infection
New agents for hepatitis C and the challenges in treating co-infected patients PCMAC
Jürgen Rockstroh, Bonn, Germany
Increases in acute hepatitis C (HCV) incidence across Europe: which regions and patient groups are affected? PCMAC
Ole Kirk, Copenhagen, Denmark
Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA PCMAC
Daniel Grint, London, UK
Panel discussion  PCMAC

Wednesday 14 November

ARVs Ups and Downs
Abacavir and the altered peptide repertoire model: clinical implications PCMAC
Simon Mallal, Perth, Australia
An investigation into frequency and reasons why patients switch antiretroviral therapy and which antiretrovirals are commonly implicated in toxicity
Alison Boyle, London, UK
Durability of FTC/TDF-containing  cART regimens in a large cohort of HIV-infected patients seen for care in Italy PCMAC
Alessandro Cozzi-Lepri, London, UK
Advanced renal disease, end-stage renal disease and renal death among HIV-positive individuals in Europe PCMAC
Lene Ryom, Copenhagen, Denmark
Recovery of eGFR in patients who develop renal complications on tenofovir PCMAC
Sophie Jose, London, UK
Panel discussion PC MAC

A Year in Review and Treatment as Prevention
My favourite 10 publications of 2011-2012 PCMAC
Pedro Cahn, Buenos Aires, Argentina
Pregnant women with HIV on ART in Europe: how many acheive the aim of undetectable viral load at term and are able to deliver vaginally? PCMAC
Karoline Aebi-Popp, Dublin, Ireland
ART use, viral suppression, and sexual behaviour among HIV-diagnosed MSM in the UK: results from the Antiretrovirals, Sexual Transmission Risk and Attitudes (ASTRA) study PC MAC
Fiona Lampe, London, UK
Increased HIV incidence in men who have sex with men despite high levels of ART use: analysis of an extensively documented epidemic PCMAC
Andrew N Phillips, London, UK
Panel discussion PCMAC

Poster Discussion Sessions: ARV Therapy PCMAC
Dolutegravir treatment response by baseline viral load and NRTI backbone in treatment-naïve HIV-infected Individuals
Joe Eron Jr, Chapel Hill, USA
Predictors of long-term HIV RNA suppression on darunavir/ritonavir monotherapy in the MONET trial
José R Arribas, Madrid, Spain
Maraviroc 150 mg QD plus lopinavir/ritonavir, a NRTIs-sparing regimen for HIV-infected naïve patients: 48-weeks final results
Silvia Nozza, Milan, Italy
Spirit: switching to emtricitabine/rilpivirine/tenofovir DF single-tablet regimen from boosted protease inhibitor maintains HIV suppression at week 48
Martin Fisher, Brighton, UK
A randomized pilot study of tenofovir/emtricitabine (TDF/FTC) + boosted atazanavir (ATV/r) vs. raltegravir (RAL BID) + ATV/r vs. RAL BID + ATV BID
Calvin J Cohen, Boston, USA

Poster Discussion Sessions: Concomitant Conditions PC MAC
Assessment of patient complexity using routinely collected data: the UK CHIC study
Caroline Sabin, London, UK
Persistence and clearance of HPV infection at anal site in a cohort of HIV positive males
Laura Comi, Milan, Italy
Particularities of tuberculosis in HIV-infected patients: 10-year experience of a Portuguese hospital
Sofia Nunes, Aveiro, Portugal
Neurocognitive impairment, depression, and anxiety in HIV-1 infected patients across western Europe and Canada: the CRANium study- ethnicity analysis
Daniel Elbirt, Rehovot, Israel
Safety and efficacy of raltegravir in patients co-infected with HIV and hepatitis B and/or C virus: complete data from Phase III double-blind studies
Jürgen Rockstroh, Bonn, Germany

Clinical Controversies PCMAC
Case-based discussion held in collaboration with European AIDS Clinical Society (EACS)
Melanie Thompson, Atlanta, USA
José Gatell, Barcelona, Spain

Sanjay Bhagani, London, UK; Joe Eron Jr, Chapel Hill, USA; Christine Katlama, Paris, France; Ian Williams, London, UK

Poster Prize Winner Announcement and Presentation PCMAC
Presented by Congress Chairperson: Ian Weller, London, UK

HIV, ARVs and the Brain
The brain and potent ART: the final frontier? PCMAC
William Powderly, Dublin, Ireland
Baseline data from the MSM Neurocog study PCMAC
Tristan Barber, London, UK
Prolonged treatment with boosted protease inhibitor monotherapy is not associated with a highter rate of neurocognitive impairment than triple drug ART PCMAC
José R Arribas, Madrid, Spain
Prevalence and risk factors for HIV CSF viral escape: results from the CHARTER and HNRP cohorts PCMAC
Ignacio Perez Valero, Madrid, Spain
Panel discussion PCMAC

Thursday 15 November

Vaccines, AIDS and Non-AIDS Events
Progress in HIV vaccine research: an outsider’s view PC MAC
Dan Kuritzkes, Boston, USA
CD4 count and viral load specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use PCMAC
Ole Kirk, Copenhagen, Denmark
Immuno-virological discordance is associated with a higher frequency of AIDS, severe non-AIDS, and death PC MAC
Alexander Zoufaly, Hamburg, Germany
Risk of AIDS-defining cancers in HIV-1-infected patients (1992-2009): results from FHDH-ANRS CO4 PCMAC
Mira Hleyhel, Paris, France
CMV co-infection and risk of AIDS and non-AIDS events in a large cohort of HIV-infected patients PCMAC
Miriam Lichtner, Polo Pontino, Italy
Panel discussion PCMAC

ART Strategies
ART strategies and new drugs PCMAC
Roy Gulick, New York, USA
Timing of cART initiation after a first AIDS-defining event (ADE): temporal changes in clinical attitudes in a large cohort of HIV-infected patients PCMAC
Antonella Cingolani, Rome, Italy
Metabolic effects of atazanivir/ritonavir vs darunavir/ritonavir in combination with tenofovir/emtricitabine in antiretroviral-naïve patients (ATADAR Study) PC MAC
Esteban Martinez, Barcelona, Spain
Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has durable efficacy and Differentiated safety compared to efavirenz/emtricitabine/tenofovir DF at week 96 in treatment-naïve HIV-1-infected patients PC MAC
Andrew Zolopa, Palo Alto, USA
Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has durable efficacy and differentiated safety compared to atazanavir boosted by ritonavir plus emtricitabine/tenofovir DF at week 96 in treatement-naïve HIV-1-infected patients PCMAC
Jürgen Rockstroh, Bonn, Germany
STAR study: single tablet regimen emtricitabine/rilpivirine/tenofovir DF is non-inferior to efavirenz/emtricitabine/tenofovir DF in ART-naïve adults PCMAC
Calvin Cohen, Boston, USA
Panel discussion  PCMAC

Closing Remarks
Closing comments from the European AIDS Treatment Goup (EATG) Chair PCMAC
Brian West, European AIDS Treatment Group (EATG), UK
Closing comments from the Congress Chair PCMAC
Ian Weller, London, UK